How to Build a Biotech Portfolio That Survives CRLs

Picking the right biotech stock is only half the battle. The other half is how much you put into it, what else you own alongside it, and when you get out. A 200% gain on an approval can add less to the bottom line than a 60% loss on a CRL subtracts if the loser was sized 3x larger. Here is the portfolio framework designed to prevent that.

The Problem

You know how to find biotech catalysts. You’ve read the trial data. You’re tracking PDUFA dates on BioPharmCatalyst. But when it’s time to actually put money to work, you either own 25 stocks you can’t track or 3 stocks where one bad CRL wipes out your year. Neither works.

The Solution

Own 8-15 biotech stocks in a dedicated portfolio. A binary event like an FDA decision should never represent more than 5% of your portfolio. A platform company with multiple pipeline shots can go to 10%. And you always keep 15-25% in cash, because biotech sells off as a sector at least twice a year and you want to buy, not panic-sell.

Step 1: Decide How Many Stocks to Own

8-15 positions is the sweet spot for a dedicated biotech portfolio. Fewer than 8 and one CRL (Complete Response Letter, the FDA’s rejection of a drug application) can crater your returns. More than 15 and you can’t meaningfully track the catalysts, trial readouts, and earnings for each position.

If biotech is just a slice of a broader portfolio, stick to 3-5 names. You’re not building a biotech fund. You’re picking your best ideas and sizing them so a binary outcome doesn’t change your retirement date.

The 2018-2022 PDUFA cycle had a 37% CRL rate across all BLAs and NDAs. That means roughly 1 in 3 drug applications gets rejected. If you own 3 stocks and one gets a CRL, a third of your biotech allocation just dropped 30-60% overnight. That math works better with 10 names than with 3.

Step 2: Size Positions by Catalyst Type

Different biotech positions carry different risk profiles, and your sizing should reflect that. Position sizing is where most investors destroy their returns, not stock selection.

Pre-PDUFA binary: 2-5% of portfolio. The stock moves 30-50% on approval or drops 30-60% on a CRL. You have zero control over the outcome. A 37% chance of losing half your position means you cannot size this like a normal stock.

Phase 3 readout: 3-7%. A positive Phase 3 is more predictable than an FDA decision, but roughly one-third of Phase 2 successes fail to replicate in Phase 3. The Phase 2 to Phase 3 transition rate is 30-45% across therapeutic areas. That number should scare you.

Platform company, long-term hold: 5-10%. Companies like Moderna (MRNA), Vertex (VRTX), or Gilead (GILD) with approved drugs and diversified pipelines. You’re betting on pipeline execution over years, not a single binary event. These positions compound.

Speculative pre-clinical: 0.5-2%. This is option money. You expect to lose it most of the time, and when one works, it works big enough to cover the others.

Step 3: Spread Your Catalysts Across the Calendar

This is the step most investors skip and the one that costs them the most. Map every position’s catalysts onto a 12-month calendar. If you have three PDUFA dates in November, you are over-concentrated on a single month even if the stocks are in different sectors.

A bad month in biotech compounds. The sector is more correlated than it looks. A negative FDA advisory committee vote on one drug can drag down the entire sector because the market re-prices regulatory risk across the board. If all your binary events cluster in 30 days, you’ve built a portfolio that rises and falls on regulatory sentiment, not on individual catalysts.

Step 4: Diversify Across Therapeutic Areas

Ten oncology stocks is not a diversified portfolio. Cancer drugs face the same FDA division (the Oncology Center of Excellence), compete for the same patient populations, and trade on the same conference cycles (ASCO in June, ESMO in October). A bad ASCO abstracts drop can hit every oncology name you own.

Spread across at least 3 therapeutic areas. One or two oncology plays, a rare disease name (Ultragenyx RARE, BridgeBio BBIO), a gene therapy holding, maybe a neuroscience bet. Different sectors have different catalyst calendars, different regulatory risks, and different investor sentiment cycles. A portfolio of 10 stocks across 5 sectors survives sector rotations. A portfolio of 10 oncology stocks doesn’t.

Step 5: Write Your Exit Rules Before You Enter

The hardest part of biotech investing is selling. You’ll talk yourself into holding a stock that’s down 40% because “the science is still good.” Sometimes it is. Usually the market knows something you don’t.

Sell when your thesis breaks, not when your P&L hurts. A stock down 40% on a CRL is not “cheap.” It’s correctly repriced for a drug that isn’t getting approved. A stock up 80% on approval isn’t “due for a pullback.” It’s correctly repriced for a drug that now generates revenue.

After a 50%+ gain on a catalyst, trim back to your original position size. You captured the binary event. The rest is commercial execution, which is a different thesis with different risks. If you still believe, re-enter with fresh sizing.

After a CRL: do not double down. The market is telling you the regulatory path changed. You can re-evaluate after the company issues its plan, but buying more before you understand what went wrong is how a 40% loss becomes a 75% loss.

Step 6: Keep Cash

Always hold 15-25% of your biotech portfolio in cash. Biotech sells off as a sector at least twice a year. A bad FDA commissioner comment, a surprise CRL on a high-profile drug, a macro rotation out of risk assets, and suddenly every biotech you track is 20-30% cheaper than last month.

That cash is not idle. It’s your call option on the next sector panic. When Sarepta (SRPT) fell to $15 on Elevidys label concerns and safety questions, the investors who bought were the ones who hadn’t been fully deployed.

Common Mistakes

Owning 30 biotech stocks. You cannot follow 30 catalysts, 30 quarterly earnings calls, and 30 clinical trial readouts. You’re running an index fund with individual stock risk.

Putting 20% of your portfolio into a pre-PDUFA stock. This is gambling, not investing. Even if you’re right 70% of the time, the 30% you’re wrong eventually wipes out the gains. The Kelly Criterion, a position-sizing formula, says the optimal bet on a binary event with 60% win probability and 80% upside vs 50% downside is roughly 13% of your bankroll. In practice, Kelly/5 (about 2-3%) is safer for biotech binaries because your probability estimates are wrong more often than you think.

Holding through a CRL without re-evaluating. The stock didn’t “go on sale.” It got repriced. Treat it as a new position with a new thesis.

Neglecting correlation. Biotech stocks move together more than you think. A diversified biotech portfolio is not diversified in a market crash. That’s what the cash is for.

Final Checklist

• 8-15 positions in a dedicated biotech portfolio (or 3-5 as a satellite allocation)
• No single binary event exceeds 5% of portfolio
• Catalysts spread across at least 6 months, not clustered in one month
• Positions span at least 3 therapeutic areas
• Exit rules written for every position before entry
• 15-25% cash reserve for sector sell-offs
• Catalyst calendar mapped 12 months forward

For more on finding the right biotech stocks in the first place, start with how to invest in biotech. If you’re trading individual FDA catalysts, the FDA catalyst trading guide has the step-by-step framework. For understanding whether a biotech is cheap or expensive, read the three valuation methods every biotech investor needs.